The Journal of Rheumatology

• 

  Publication Venue For

  • Core Outcome Sets Specifically for Longterm Observational Studies: OMERACT Special Interest Group Update in Rheumatoid Arthritis..  46:1164-1167. 2019
  • Identifying Possible Outcome Domains from Existing Outcome Measures to Inform an OMERACT Core Domain Set for Safety in Rheumatology Trials..  46:1173-1178. 2019
  • Endorsement of the 66/68 Joint Count for the Measurement of Musculoskeletal Disease Activity: OMERACT 2018 Psoriatic Arthritis Workshop Report..  46:996-1005. 2019
  • PsAID12 Provisionally Endorsed at OMERACT 2018 as Core Outcome Measure to Assess Psoriatic Arthritis-specific Health-related Quality of Life in Clinical Trials..  46:990-995. 2019
  • Is It Time for Gout Flare Treatment to Move into the 21st Century?.  46:667-669. 2019
  • Fertility and Ovarian Reserve among Women with Rheumatoid Arthritis..  46:455-459. 2019
  • Is Traditional Chinese Medicine Use Associated with Worse Patient-reported Outcomes among Chinese American Rheumatology Patients? 2019
  • It Is Time to Modify Treatment to Enable More Women with Rheumatoid Arthritis to Have Successful Pregnancies..  46:223-225. 2019
  • Hydroxychloroquine Levels throughout Pregnancies Complicated by Rheumatic Disease: Implications for Maternal and Neonatal Outcomes..  46:57-63. 2019
  • Preconceptional Cardiovascular Health and Pregnancy Outcomes in Women with Systemic Lupus Erythematosus..  46:70-77. 2019
  • New Features for Measuring Disease Activity in Pediatric Localized Scleroderma..  45:1680-1688. 2018
  • The Patient Research Partner Network Matures: A Report from the GRAPPA 2017 Annual Meeting.  45:52-53. 2018
  • Adiposity in Juvenile Psoriatic Arthritis..  45:411-418. 2018
  • Critical Outcomes in Longitudinal Observational Studies and Registries in Patients with Rheumatoid Arthritis: An OMERACT Special Interest Group Report..  44:1894-1898. 2017
  • Developing an OMERACT Core Outcome Set for Assessing Safety Components in Rheumatology Trials: The OMERACT Safety Working Group..  44:1916-1919. 2017
  • Validating Rheumatoid Arthritis Remission Using the Patients' Perspective: Results from a Special Interest Group at OMERACT 2016..  44:1889-1893. 2017
  • Health Equity Considerations for Developing and Reporting Patient-reported Outcomes in Clinical Trials: A Report from the OMERACT Equity Special Interest Group..  44:1727-1733. 2017
  • Malignancy in Pediatric-onset Systemic Lupus Erythematosus..  44:1484-1486. 2017
  • Updating the Psoriatic Arthritis (PsA) Core Domain Set: A Report from the PsA Workshop at OMERACT 2016..  44:1522-1528. 2017
  • Defining Outcome Measures for Psoriatic Arthritis: A Report from the GRAPPA-OMERACT Working Group..  44:697-700. 2017
  • Proceedings of the GRAPPA 2016 Retreat..  44:668-673. 2017
  • Tackling Patient Centricity: A Report from the GRAPPA 2016 Annual Meeting..  44:703-705. 2017
  • Childhood Arthritis and Rheumatology Research Alliance Consensus Clinical Treatment Plans for Juvenile Dermatomyositis with Persistent Skin Rash..  44:110-116. 2017
  • Gene Expression Profiling in Blood and Affected Muscle Tissues Reveals Differential Activation Pathways in Patients with New-onset Juvenile and Adult Dermatomyositis..  44:117-124. 2017
  • The Systemic Juvenile Idiopathic Arthritis Cohort of the Childhood Arthritis and Rheumatology Research Alliance Registry: 2010-2013..  43:1755-1762. 2016
  • Identifying Targets for Improving Mental Healthcare of Adolescents with Systemic Lupus Erythematosus: Perspectives from Pediatric Rheumatology Clinicians in the United States and Canada..  43:1136-1145. 2016
  • Let's Talk about Inclusion: A Report on Patient Research Partner Involvement in the GRAPPA 2015 Annual Meeting..  43:970-973. 2016
  • Report of the GRAPPA-OMERACT Psoriatic Arthritis Working Group from the GRAPPA 2015 Annual Meeting..  43:965-969. 2016
  • Remission in Rheumatoid Arthritis: Working Toward Incorporation of the Patient Perspective at OMERACT 12..  43:203-207. 2016
  • The Performance and Association Between Patient-reported and Performance-based Measures of Physical Functioning in Research on Individuals with Arthritis..  43:131-137. 2016
  • Autoantibodies to Dense Fine Speckles in Pediatric Diseases and Controls..  42:2419-2426. 2015
  • Pregnancy Outcomes in Subjects Exposed to Certolizumab Pegol..  42:2270-2278. 2015
  • Toward Ensuring Health Equity: Readability and Cultural Equivalence of OMERACT Patient-reported Outcome Measures..  42:2448-2459. 2015
  • Enhanced Patient Involvement and the Need to Revise the Core Set - Report from the Psoriatic Arthritis Working Group at OMERACT 2014..  42:2198-2203. 2015
  • Consensus on the Need for a Hierarchical List of Patient-reported Pain Outcomes for Metaanalyses of Knee Osteoarthritis Trials: An OMERACT Objective..  42:1971-1975. 2015
  • Current State of Reporting Pain Outcomes in Cochrane Reviews of Chronic Musculoskeletal Pain Conditions and Considerations for an OMERACT Research Agenda..  42:1934-1942. 2015
  • The role of innate immunity in osteoarthritis: when our first line of defense goes on the offensive..  42:363-371. 2015
  • Building bridges between researchers and patient research partners: A report from the grappa 2014 annual meeting.  42:1021-1026. 2015
  • Review of the psoriatic arthritis working group at OMERACT 12: A report from the GRAPPA 2014 annual meeting.  42:1048-1051. 2015
  • Extension study of participants from the trial of early aggressive therapy in juvenile idiopathic arthritis..  41:2459-2465. 2014
  • Tumor necrosis factor-α inhibitor treatment and the risk of incident cardiovascular events in patients with early rheumatoid arthritis: a nested case-control study..  41:2129-2136. 2014
  • Adipose depots, not disease-related factors, account for skeletal muscle insulin sensitivity in established and treated rheumatoid arthritis..  41:1974-1979. 2014
  • Rilonacept for gout flare prevention in patients receiving uric acid-lowering therapy: results of RESURGE, a phase III, international safety study..  41:1703-1711. 2014
  • Clinically inactive disease in a cohort of children with new-onset polyarticular juvenile idiopathic arthritis treated with early aggressive therapy: time to achievement, total duration, and predictors..  41:1163-1170. 2014
  • Patient participation in psoriasis and psoriatic arthritis outcome research: a report from the GRAPPA 2013 Annual Meeting..  41:1206-1211. 2014
  • Associations between biomarkers of joint metabolism, hand osteoarthritis, and hand pain and function: the Johnston County Osteoarthritis Project..  41:938-944. 2014
  • Causal attributions about disease onset and relapse in patients with systemic vasculitis..  41:923-930. 2014
  • Development of a disease activity and responder index for psoriatic arthritis--report of the Psoriatic Arthritis Module at OMERACT 11..  41:782-791. 2014
  • OMERACT endorsement of measures of outcome for studies of acute gout..  41:569-573. 2014
  • Erratum: Proliferative lupus nephritis and leukocytoclastic vasculitis during treatment with etanercept (Journal of Rheumatology (2005) 32 (740-743)).  41:2336. 2014
  • Longitudinal peripheral blood lymphocyte subsets correlate with decreased disease activity in juvenile dermatomyositis..  40:1200-1211. 2013
  • Decreased Expression of Nicotinamide Phosphoribosyltransferase in Patients with Juvenile Idiopathic Arthritis Receiving Methotrexate.  40:741-742. 2013
  • Gastric antral vascular ectasia and its clinical correlates in patients with early diffuse systemic sclerosis in the SCOT trial..  40:455-460. 2013
  • BAFF expression correlates with idiopathic inflammatory myopathy disease activity measures and autoantibodies..  40:294-302. 2013
  • Comparative effectiveness of nonbiologic versus biologic disease-modifying antirheumatic drugs for rheumatoid arthritis..  40:127-136. 2013
  • Enthesitis-related arthritis is associated with higher pain intensity and poorer health status in comparison with other categories of juvenile idiopathic arthritis: the Childhood Arthritis and Rheumatology Research Alliance Registry..  39:2341-2351. 2012
  • The Myositis Activities Profile -- initial validation for assessment of polymyositis/dermatomyositis in the USA..  39:2134-2141. 2012
  • Do adult disease severity subclassifications predict use of cyclophosphamide in children with ANCA-associated vasculitis? An analysis of ARChiVe study treatment decisions..  39:2012-2020. 2012
  • Increased sensitivity of the European medicines agency algorithm for classification of childhood granulomatosis with polyangiitis..  39:1687-1697. 2012
  • Colchicine use is associated with decreased prevalence of myocardial infarction in patients with gout..  39:1458-1464. 2012
  • Assessing the performance of the Birmingham Vasculitis Activity Score at diagnosis for children with antineutrophil cytoplasmic antibody-associated vasculitis in A Registry for Childhood Vasculitis (ARChiVe)..  39:1088-1094. 2012
  • How do physicians weigh benefits and risks associated with treatments in patients with osteoarthritis in the United Kingdom?.  39:1056-1063. 2012
  • Dysregulation of the microvasculature in nonlesional non-sun-exposed skin of patients with lupus nephritis (Journal of Rheumatology (2012) 39, (510-515)).  39:881. 2012
  • Dysregulation of the microvasculature in nonlesional non-sun-exposed skin of patients with lupus nephritis..  39:510-515. 2012
  • Racial differences in knee osteoarthritis pain: potential contribution of occupational and household tasks..  39:337-344. 2012
  • Developing a Construct to Evaluate Flares in Rheumatoid Arthritis: A Conceptual Report of the OMERACT RA Flare Definition Working Group.  38:1745-1750. 2011
  • Relationship between markers of platelet activation and inflammation with disease activity in Wegener's granulomatosis..  38:1048-1054. 2011
  • The clinical utility of measuring complement and anti-dsDNA antibodies during pregnancy in patients with systemic lupus erythematosus..  38:1012-1016. 2011
  • Platelet microparticles: making blood a bad humor..  38:590-592. 2011
  • Autoimmune disease incidence among women prenatally exposed to diethylstilbestrol..  37:2167-2173. 2010
  • Hazard of incident and progressive knee and hip radiographic osteoarthritis and chronic joint symptoms in individuals with and without limb length inequality..  37:2133-2140. 2010
  • Treatment approaches to juvenile dermatomyositis (JDM) across North America: The Childhood Arthritis and Rheumatology Research Alliance (CARRA) JDM Treatment Survey..  37:1953-1961. 2010
  • Associations of occupational tasks with knee and hip osteoarthritis: the Johnston County Osteoarthritis Project..  37:842-850. 2010
  • Effectiveness and Toxicity of Methotrexate in Juvenile Idiopathic Arthritis: Comparison of 2 Initial Dosing Regimens.  37:870-875. 2010
  • HMGB1: a dangerous player in lupus pathogenesis..  37:689-691. 2010
  • Perceived functioning has ethnic-specific associations in systemic sclerosis: another dimension of personalized medicine..  36:2724-2732. 2009
  • The localized scleroderma skin severity index and physician global assessment of disease activity: a work in progress toward development of localized scleroderma outcome measures..  36:2819-2829. 2009
  • Randomized placebo-controlled crossover trial of tadalafil in Raynaud's phenomenon secondary to systemic sclerosis..  36:2264-2268. 2009
  • Urine osteoprotegerin and monocyte chemoattractant protein-1 in lupus nephritis..  36:2224-2230. 2009
  • Proposal for levels of evidence schema for validation of a soluble biomarker reflecting damage endpoints in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis, and recommendations for study design..  36:1792-1799. 2009
  • Reappraisal of OMERACT 8 draft validation criteria for a soluble biomarker reflecting structural damage endpoints in rheumatoid arthritis, psoriatic arthritis, and spondyloarthritis: the OMERACT 9 v2 criteria..  36:1785-1791. 2009
  • Testing of the OMERACT 8 draft validation criteria for a soluble biomarker reflecting structural damage in rheumatoid arthritis: a systematic literature search on 5 candidate biomarkers..  36:1769-1784. 2009
  • Quality of life and disability in patients with treatment-failure gout..  36:1041-1048. 2009
  • Catastrophic Antiphospholipid Syndrome in the Central Nervous System: Figure 1..  36:651-651. 2009
  • Current therapies for lupus nephritis in an ethnically heterogeneous cohort..  36:298-305. 2009
  • Polyarteritis Nodosa and Antiphospholipid Syndrome Causing Bilateral Renal Infarction.  36:197-197. 2009
  • Bone scanning of limited value for diagnosis of symptomatic oligofocal and multifocal osteonecrosis..  35:1629-1634. 2008
  • Hodgkin's lymphoma and tumor necrosis factor inhibitors in juvenile idiopathic arthritis..  35:1680-1681. 2008
  • Osteoarthritis and sleep: the Johnston County Osteoarthritis Project..  35:1102-1107. 2008
  • Epidemiology of sporadic inclusion body myositis and polymyositis in Olmsted County, Minnesota..  35:445-447. 2008
  • The frequency of anticardiolipin antibodies and genetic mutations associated with hypercoagulability among patients with Wegener's granulomatosis with and without history of a thrombotic event..  34:2446-2450. 2007
  • Association of anemia and physical disability among patients with rheumatoid arthritis..  34:2177-2182. 2007
  • The value of measuring variability in osteoarthritis pain..  34:2132-2133. 2007
  • Peripheral blood expression of nuclear factor-kappab-regulated genes is associated with rheumatoid arthritis disease activity and responds differentially to anti-tumor necrosis factor-alpha versus methotrexate..  34:1817-1822. 2007
  • Changes in biomarkers of inflammation and bone turnover and associations with clinical efficacy following infliximab plus methotrexate therapy in patients with early rheumatoid arthritis..  34:1465-1474. 2007
  • Antiendothelial cell antibodies in patients with Wegener's granulomatosis: prevalence and correlation with disease activity and manifestations..  34:1027-1031. 2007
  • Development of draft validation criteria for a soluble biomarker to be regarded as a valid biomarker reflecting structural damage endpoints in rheumatoid arthritis and spondyloarthritis clinical trials..  34:634-640. 2007
  • Role of thrombotic and fibrinolytic alterations in the pathogenesis and treatment of osteonecrosis..  34:466-468. 2007
  • Testing of the preliminary OMERACT validation criteria for a biomarker to be regarded as reflecting structural damage endpoints in rheumatoid arthritis clinical trials: the example of C-reactive protein..  34:623-633. 2007
  • Influence of oxygen tension on interleukin 1-induced peroxynitrite formation and matrix turnover in articular cartilage..  34:401-407. 2007
  • Enzyme elevation in patients with juvenile dermatomyositis and steroid myopathy..  33:1392-1394. 2006
  • A boy with fever and whorl keratopathy..  33:1210-1211. 2006
  • Precocious osteoarthritis in a family with recurrent COL2A1 mutation..  33:1133-1136. 2006
  • Arthritis prevalence and symptoms among US non-veterans, veterans, and veterans receiving Department of Veterans Affairs Healthcare..  33:348-354. 2006
  • Anti-tumor necrosis factor-alpha therapy augments dipeptidyl peptidase IV activity and decreases autoantibodies to GRP78/BIP and phosphoglucose isomerase in patients with rheumatoid arthritis..  32:2116-2124. 2005
  • Efficacy of milnacipran in patients with fibromyalgia..  32:1975-1985. 2005
  • Erratum: Patient preference in a crossover clinical trial of patients with osteoarthritis of the knee or hip: Face validity of self-report questionnaire ratings (Journal of Rheumatology (2005) 32 (533-539)).  32:966. 2005
  • Kidney disease other than renal crisis in patients with diffuse scleroderma..  32:649-655. 2005
  • Proliferative lupus nephritis and leukocytoclastic vasculitis during treatment with etanercept..  32:740-743. 2005
  • Patient preference in a crossover clinical trial of patients with osteoarthritis of the knee or hip: face validity of self-report questionnaire ratings..  32:533-539. 2005
  • Warfarin in antiphospholipid syndrome--time to explore new horizons..  32:208-212. 2005
  • High dose immunotherapy with stem cell rescue in severe systemic sclerosis: an idea that is moving forward..  31:2331-2335. 2004
  • Niacin-like reaction to infliximab infusion in systemic juvenile rheumatoid arthritis..  31:2529-2530. 2004
  • Occupational risk factors for the development of systemic lupus erythematosus..  31:1928-1933. 2004
  • N-acetyl transferase genotypes in relation to risk of developing systemic lupus erythematosus..  31:76-80. 2004
  • Nonsteroidal antiinflammatory drug toxicity monitoring and safety practices..  30:2680-2688. 2003
  • Racial differences in health care utilization among patients with osteoarthritis..  30:2201-2206. 2003
  • Surgical management of the rheumatoid hand: consensus and controversy among rheumatologists and hand surgeons..  30:1464-1472. 2003
  • Digital necrosis related to carboplatin and gemcitabine therapy in systemic sclerosis..  30:1341-1343. 2003
  • B cell loss leading to remission in severe systemic lupus erythematosus..  30:412-414. 2003
  • Glutathione S-transferase M null homozygosity and risk of systemic lupus erythematosus associated with sun exposure: a possible gene-environment interaction for autoimmunity..  30:276-282. 2003
  • Health status of patients with juvenile rheumatoid arthritis at 1 and 5 years after diagnosis..  30:394-400. 2003
  • Nitric oxide synthase 2 promoter polymorphisms and systemic lupus erythematosus in african-americans..  30:60-67. 2003
  • Frequency of abnormal hand and wrist radiographs at time of diagnosis of polyarticular juvenile rheumatoid arthritis..  29:2214-2218. 2002
  • Improving physical functional status in patients with fibromyalgia: a brief cognitive behavioral intervention..  29:1280-1286. 2002
  • Open label study to assess infliximab safety and timing of onset of clinical benefit among patients with rheumatoid arthritis..  29:667-677. 2002
  • Chronic widespread musculoskeletal pain with or without fibromyalgia: psychological distress in a representative community adult sample..  29:588-594. 2002
  • Wegener's granulomatosis: survey of 701 patients in North America. Changes in outcome in the 1990s..  29:309-316. 2002
  • Smoking and use of hair treatments in relation to risk of developing systemic lupus erythematosus..  28:2653-2656. 2001
  • Dolorimetry performed at 3 paired tender points highly predicts overall tenderness..  28:2568-2569. 2001
  • Autologous stem cell transplantation for pediatric rheumatic diseases..  28:2337-2358. 2001
  • Risk factors associated with thrombosis in patients with antiphospholipid antibodies..  28:2018-2024. 2001
  • Development of systemic lupus erythematosus following autologous bone marrow transplant for acute lymphocytic leukemia..  28:1467-1468. 2001
  • Large artery vasculitis following recombinant hepatitis B vaccination: 2 cases..  28:1116-1120. 2001
  • Silicone gel breast implant rupture, extracapsular silicone, and health status in a population of women..  28:996-1003. 2001
  • Validation of the Childhood Health Assessment Questionnaire in the juvenile idiopathic myopathies. Juvenile Dermatomyositis Disease Activity Collaborative Study Group..  28:1106-1111. 2001
  • Effects of inherited thrombophilic mutations in an adolescent with antiphospholipid syndrome and systemic lupus erythematosus..  28:370-372. 2001
  • A general population study of fibromyalgia tender points in noninstitutionalized adults with chronic widespread pain..  27:2677-2682. 2000
  • Treatment of rheumatoid arthritis with a DR4/1 peptide..  27:1855-1863. 2000
  • Serum levels of soluble CD44 in primary Sjögren's syndrome..  27:1444-1449. 2000
  • Things do not get better by being left alone. The physician and complementary medicine..  27:1332-1333. 2000
  • Chimeric anti-tumor necrosis factor-alpha monoclonal antibody treatment of patients with rheumatoid arthritis receiving methotrexate therapy..  27:841-850. 2000
  • Perspectives on posttraumatic fibromyalgia: a random survey of Canadian general practitioners, orthopedists, physiatrists, and rheumatologists..  27:790-796. 2000
  • Prominent expression of mRNA for proinflammatory cytokines in synovium in patients with juvenile rheumatoid arthritis or chronic Lyme arthritis..  27:497-503. 2000
  • Familial dermatomyositis..  26:2691-2692. 1999
  • Specificity of antibodies to bacterial DNA in the sera of healthy human subjects and patients with systemic lupus erythematosus..  26:1934-1938. 1999
  • The London Fibromyalgia Epidemiology Study: comparing the demographic and clinical characteristics in 100 random community cases of fibromyalgia versus controls..  26:1577-1585. 1999
  • The London Fibromyalgia Epidemiology Study: the prevalence of fibromyalgia syndrome in London, Ontario..  26:1570-1576. 1999
  • Early undifferentiated connective tissue disease (CTD). VI. An inception cohort after 10 years: disease remissions and changes in diagnoses in well established and undifferentiated CTD..  26:816-825. 1999
  • Testing an instrument to screen for fibromyalgia syndrome in general population studies: the London Fibromyalgia Epidemiology Study Screening Questionnaire..  26:880-884. 1999
  • The London Fibromyalgia Epidemiology Study: direct health care costs of fibromyalgia syndrome in London, Canada..  26:885-889. 1999
  • Mycophenolate mofetil suppresses autoimmunity and mortality in the female NZB x NZW F1 mouse model of systemic lupus erythematosus..  25:2364-2370. 1998
  • A cross sectional analysis of 5 different markers of collagen degradation in rheumatoid arthritis..  25:1472-1479. 1998
  • Nitric oxide--friend or foe in arthritis?.  25:1451-1453. 1998
  • Immunogenetic studies in families of children with juvenile dermatomyositis..  25:1000-1002. 1998
  • Anti-DNA antibodies in systemic lupus erythematosus: a case of mistaken identity?.  25:195-197. 1998
  • Transforming growth factor-beta 1 and 2 in the synovial-like interface membrane between implant and bone in loosening of total hip arthroplasty..  24:694-701. 1997
  • Interleukin-2 receptor levels in sera of patients with rheumatoid arthritis treated with sulfasalazine, parenteral gold, or placebo..  23:1856-1861. 1996
  • A multicenter trial of recombinant human interferon gamma in patients with systemic sclerosis: effects on cutaneous fibrosis and interleukin 2 receptor levels..  23:654-658. 1996
  • The fibromyalgia syndrome: a consensus report on fibromyalgia and disability..  23:534-539. 1996
  • Transcranial doppler sonography to monitor cerebral vasculitis..  23:561-563. 1996
  • Potential pathogenicity of deglycosylated IgG cross reactive with streptokinase and fibronectin in the serum of patients with rheumatoid arthritis..  23:44-51. 1996
  • Breast feeding and the development of juvenile rheumatoid arthritis..  22:1166-1170. 1995
  • Fibromyalgia in rheumatology practice: a survey of Canadian rheumatologists..  22:722-726. 1995
  • Measuring shoulder function with the Shoulder Pain and Disability Index..  22:727-732. 1995
  • Cooccurrence of collagenous colitis with seronegative spondyloarthropathy: report of a case and literature review..  20:2153-2157. 1993
  • The effects of nonsteroidal antiinflammatory drug therapy in early rheumatoid arthritis on serum levels of soluble interleukin 2 receptor, CD4, and CD8..  20:1857-1862. 1993
  • Presentation of multicentric Castleman's disease with sicca syndrome, cardiomyopathy, palmar and plantar rash..  20:1588-1591. 1993
  • A randomized controlled trial of home exercise on the rheumatoid hand..  20:785-789. 1993
  • Diagnosis of crystal induced arthritis by dark field microscopy..  20:921-924. 1993
  • Association of methotrexate, rheumatoid arthritis and lymphoma: report of 2 cases and literature review..  19:1462-1465. 1992
  • Generic versus disease specific health status measures: comparing the sickness impact profile and the arthritis impact measurement scales..  19:543-546. 1992
  • Lymphoma developing in a patient with rheumatoid arthritis taking low dose weekly methotrexate..  18:1741-1743. 1991
  • Large vessel vasculitis of the central nervous system in systemic lupus erythematosus: report and review of the literature..  18:748-751. 1991
  • Discrimination of antineutrophil antibodies from antinuclear antibodies using immunofluorescence on neutrophils and HL60 cells..  18:575-579. 1991
  • Serum immunoglobulin levels in systemic lupus erythematosus: the effects of age, sex, race and disease duration..  18:540-544. 1991
  • The relationship between soluble interleukin 2 receptor levels and antidouble stranded DNA antibody levels in patients with systemic lupus erythematosus..  18:235-240. 1991
  • Mixed connective tissue disease with arterial thrombosis, antiphospholipid antibodies and heparin induced thrombocytopenia..  17:1523-1524. 1990
  • Clinical rheumatology training of primary care physicians: the resident perspective..  17:666-672. 1990
  • Patterns of autoantibody expression in pediatric and adult systemic lupus erythematosus..  16:1329-1334. 1989
  • Reduction of indomethacin induced gastroduodenal mucosal injury and gastrointestinal symptoms with cimetidine in normal subjects..  16:1249-1252. 1989
  • Antidouble stranded DNA antibody assays in systemic lupus erythematosus: correlations of longitudinal antibody measurements..  16:609-613. 1989
  • Early detection of carpal erosions in patients with rheumatoid arthritis: a pilot study of magnetic resonance imaging..  15:1361-1366. 1988
  • The relationship of anticardiolipin antibodies to disease manifestations in pediatric systemic lupus erythematosus..  15:1389-1394. 1988
  • Ureaplasma urealyticum septic arthritis in hypogammaglobulinemia..  15:369-371. 1988
  • Bilateral silicone induced synovitis of the wrist..  14:1202-1205. 1987
  • Pyomyositis and polyarticular septic arthritis from Hemophilus influenzae in a nonimmunocompromised adult..  14:1190-1192. 1987
  • The assessment of pain in rheumatoid arthritis: disease differentiation and temporal stability of a behavioral observation method..  14:700-704. 1987
  • Membrane attack complex of complement in rheumatoid synovial tissue demonstrated by immunofluorescent microscopy..  13:1028-1034. 1986
  • Aspergillus flavus: an unusual cause of chest wall inflammation in an immunocompetent host..  13:660-662. 1986
  • Septic arthritis due to Micrococcus luteus..  13:659-660. 1986
  • Pectoralis pyomyositis: an unusual cause of chest wall pain in a patient with diabetes mellitus and rheumatoid arthritis..  13:434-436. 1986
  • Reticuloendothelial system fc receptor function in rheumatoid arthritis..  10:550-557. 1983
  • Independent expression of autoantibodies in systemic lupus erythematosus..  9:691-695. 1982
  • Characterization and comparison of commercially available antinuclear antibody kits using single pattern index sera..  7:339-347. 1980
  • Rheumatoid nodulosis. Sporadic and familial diseases..  6:286-292. 1979
  • Recommendations for the Involvement of Patient Research Partners (PRP) in OMERACT Working Groups. A Report from the OMERACT 2014 Working Group on PRP. 2016
  • Developing a construct to evaluate flares in rheumatoid arthritis: a conceptual report of the OMERACT RA Flare Definition Working Group. 2011
  • Toward development of a fibromyalgia responder index and disease activity score: OMERACT module update. 2011
  • Open-Label Certolizumab Pegol Is Effective In Patients Who Withdrew From Double-Blind Treatment Due To Non-Response 2010
  • Safety Update on Certolizumab Pegol (CZP) in Patients with Active Rheumatoid Arthritis (RA) 2010
  • The Efficacy of Certolizumab Pegol Added to Methotrexate is Sustained Over 2 Years in the Treatment of Rheumatoid Arthritis 2010
  • Certolizumab Pegol Inhibits Radiographic Progression at 16 Weeks of Treatment. Results from Two RCTs (RAPID 1 And 2) 2009
  • Content and criterion validity of the preliminary core dataset for clinical trials in fibromyalgia syndrome. 2009
  • Fibromyalgia syndrome module at OMERACT 9: domain construct. 2009
  • The OMERACT-ICF Reference Group: integrating the ICF into the OMERACT process: opportunities and challenges. 2009
  • Proposal for Levels of Evidence Schema for Validation of a Soluble Biomarker Reflecting Damage Endpoints in Rheumatoid Arthritis, Psoriatic Arthritis, and Ankylosing Spondylitis, and Recommendations for Study Design 2009
  • Fibromyalgia syndrome. 2007